Utilização de medicamentos por gestantes em atendimento pré-natal em uma maternidade do município de Ribeirão Preto-SP

FONTOURA, A. Drug utilization for pregnant women in prenatal care in maternity of Ribeirao Preto – SP. 2009 121f, Dissertation (Master). Faculdade de Ciencias Farmaceuticas de Ribeirao Preto – Universidade de Sao Paulo, Ribeirao Preto, 2009. Pregnant women can present health problems that often require the use of drugs. Therefore, the drugs utilization studies during pregnancy are relevant due to the potential risks that drugs can provide to the fetus, besides, they can prevent the indiscriminate use of drugs during pregnancy. The purpose of this study was to describe drugs used during pregnancy for pregnant women in prenatal care in maternity of Ribeirao Preto SP. A cross-sectional descriptive study was used. A total of 699 pregnant women who were at the minimum in the 30th week of gestation participated in the study. Data were collected from June 2008 to November 2008 using a structured form. For data collecting the pregnant women answered a structured form and previously tested with 44 questions including their socioeconomic-demographic data, besides specific questions about their pregnancy and drugs used during it. The profile was a pregnant woman of mean age 24.9 years old, housewife, high schooled, living with a partner and on her second pregnancy. About 20% of pregnant women began prenatal care in their 12th week of gestation and 75.3% had at least six pre-natal consultations. From 699 pregnant women interviewed, the use of at least one drug during pregnancy was reported by 98% of them. The mean of the drugs used by pregnant woman was of 4.35. The drugs most used by the pregnant women were ferrous sulfate (70.4%), acetaminophen (57.8%), antitetanic and diphtheria vaccine (46.9%) and an ointment gynecology unidentified (31.9%). Only 20% of the pregnant women used folic acid during pregnancy. According to the FDA risk classification, of all drugs used by pregnant women, 20.55% belonged to category A risk, 25.20% to category B, 14.07% to category C, 1.85% to category D, 0.03% to category X and 38.30% of the drugs used by pregnant women were not identified or were not classified by the FDA. Thus, the findings of this study are similar to those described in the literature. Pregnant women have been exposed to a variety of drugs and there is a need to improve the quality of care to pregnant women in order to prevent potential risks to the fetus, especially in relation to the use of drugs.